Tag: Pharmaceutical Deal

Novartis intends to acquire biopharmaceutical company Endocyte

Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment.

Dr. Reddy’s to sale its API manufacturing business unit in India

dr reddy s
Dr. Reddy’s Laboratories entered into a definitive agreement for the sale of its API manufacturing business unit to Therapiva Private, an emerging generics pharmaceutical company.

Cellular Biomedicine Group strikes a CAR-T deal with Novartis

Cellular Biomedicine Group (China) announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah in China.

Alexion Pharmaceuticals acquires Syntimmune biotech

Alexion Pharmaceuticals and Syntimmune entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company.

Cerveau Technologies and Ionis Pharmaceuticals set up a partnership

alzheimer's disease
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Ionis neurodegenerative disease research studies.

Allergan acquires neurotoxin biotech Bonti

Allergan announced it has agreed to acquire Bonti, a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs.

PCI Pharma Services to buy Sherpa Clinical Packaging

clinical trials
Leading global biopharmaceutical outsourcing services provider PCI Pharma Services announced the acquisition of San Diego-based Sherpa Clinical Packaging, which expands PCI’s U.S. operations.

BTG acquired a medical device maker Novate Medical

BTG, the global specialist healthcare company, announced it has acquired Novate Medical, a medical device company focused on the prevention of pulmonary embolism (PE).

Novartis sells parts of its Sandoz US portfolio to Aurobindo Pharma

Novartis announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma.

LEO Pharma signed a global licensing agreement with JW Pharmaceutical

LEO Pharma A/S (Denmark) and JW Pharmaceutical (South Korea) announced, that they have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601.

Emergent BioSolutions aquires Adapt Pharma

lab research
Emergent BioSolutions announced that it has entered into an agreement to acquire Adapt Pharma and its product NARCAN Nasal Spray, the only needle-free formulation of naloxone approved by FDA.

PTC Therapeutics buys a biotech focused on gene therapy

PTC Therapeutics announced that it has successfully completed the acquisition of Agilis Biotherapeutics, a private biotechnology company.

Novo Nordisk acquired British specialist chemistry company Ziylo

novo nordisk
Ziylo and Novo Nordisk announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK.

Astellas buys British gene therapy company Quethera

Astellas Pharma and Quethera Limited announced that Astellas has acquired Quethera, a gene therapy company, that is focused on developing novel treatments for ocular disorders, such as glaucoma.

Emergent BioSolutions buys PaxVax and its portfolio

test tubes
Emergent BioSolutions has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for $270 million.

Glenmark signs license agreement with Harbour Med

Glenmark Pharmaceuticals S.A. and Harbour BioMed announced that they have entered into an exclusive license agreement for the Greater China territory to develop, manufacture and commercialize GBR 1302,